CA2469644C - Method for large scale production of virus antigen - Google Patents

Method for large scale production of virus antigen Download PDF

Info

Publication number
CA2469644C
CA2469644C CA2469644A CA2469644A CA2469644C CA 2469644 C CA2469644 C CA 2469644C CA 2469644 A CA2469644 A CA 2469644A CA 2469644 A CA2469644 A CA 2469644A CA 2469644 C CA2469644 C CA 2469644C
Authority
CA
Canada
Prior art keywords
virus
cells
culture
cell
microcarrier
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA2469644A
Other languages
English (en)
French (fr)
Other versions
CA2469644A1 (en
Inventor
Manfred Reiter
Wolfgang Mundt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ology Bioservices Inc
Original Assignee
Baxter Healthcare SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21723079&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2469644(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Baxter Healthcare SA filed Critical Baxter Healthcare SA
Publication of CA2469644A1 publication Critical patent/CA2469644A1/en
Application granted granted Critical
Publication of CA2469644C publication Critical patent/CA2469644C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
CA2469644A 2001-12-10 2002-12-10 Method for large scale production of virus antigen Expired - Lifetime CA2469644C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/006,881 2001-12-10
US10/006,881 US6951752B2 (en) 2001-12-10 2001-12-10 Method for large scale production of virus antigen
PCT/EP2002/014011 WO2003054174A1 (en) 2001-12-10 2002-12-10 Method for large scale production of virus antigen

Publications (2)

Publication Number Publication Date
CA2469644A1 CA2469644A1 (en) 2003-07-03
CA2469644C true CA2469644C (en) 2013-07-23

Family

ID=21723079

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2469644A Expired - Lifetime CA2469644C (en) 2001-12-10 2002-12-10 Method for large scale production of virus antigen

Country Status (17)

Country Link
US (2) US6951752B2 (enExample)
EP (3) EP1894998A1 (enExample)
JP (2) JP4370511B2 (enExample)
CN (2) CN101100657B (enExample)
AT (1) ATE447010T2 (enExample)
AU (1) AU2002358662B2 (enExample)
CA (1) CA2469644C (enExample)
DE (2) DE122010000025I1 (enExample)
DK (2) DK2330189T3 (enExample)
ES (2) ES2488818T3 (enExample)
FR (1) FR10C0026I1 (enExample)
HU (1) HU225791B1 (enExample)
MX (1) MXPA04005644A (enExample)
NO (1) NO20042910L (enExample)
PL (1) PL208232B1 (enExample)
RU (1) RU2314344C2 (enExample)
WO (1) WO2003054174A1 (enExample)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7445924B2 (en) 2000-11-23 2008-11-04 Bavarian Nordic A/S Modified Vaccinia Ankara virus variant and cultivation method
US6951752B2 (en) * 2001-12-10 2005-10-04 Bexter Healthcare S.A. Method for large scale production of virus antigen
ATE302268T1 (de) * 2001-12-20 2005-09-15 Bavarian Nordic As Methode zur gewinnung und reinigung von poxviren aus infizierten zellen
ES2305514T5 (es) 2002-09-05 2019-06-14 Bavarian Nordic As Método para la amplificación de un poxvirus en condiciones exentas de suero
TWI312368B (en) * 2002-12-23 2009-07-21 Bristol Myers Squibb Compan Mammalian cell culture processes for protein production
CA2551026A1 (en) * 2003-12-23 2005-07-14 Schering Corporation Methods for producing a549 cell lines stable in serum-free medium suspension culture
JP2007522814A (ja) 2004-02-23 2007-08-16 クルセル ホランド ベー ヴェー ウイルスの精製方法
WO2005103235A1 (ja) * 2004-04-19 2005-11-03 Denka Seiken Co., Ltd. ウイルスの生産方法
NZ551640A (en) * 2004-05-20 2010-05-28 Id Biomedical Corp Process for the production of an influenza vaccine
EP1831353B1 (en) * 2004-12-23 2012-02-29 MedImmune, LLC Non-tumorigenic mdck cell line for propagating viruses
US7344839B2 (en) * 2004-12-23 2008-03-18 Aurx, Inc. Virus preparations and methods
AU2007245192B2 (en) 2006-03-31 2012-04-12 Wisconsin Alumni Research Foundation High titer recombinant influenza viruses for vaccines
KR101464783B1 (ko) 2006-09-15 2014-11-26 메디뮨 엘엘씨 높은 역가로 바이러스 증식을 지원하는 ｍｄｃｋ 세포주 및 이를 이용한 생물반응기 공정
JP5084214B2 (ja) * 2006-09-29 2012-11-28 一般財団法人日本ポリオ研究所 Ｉｐｖワクチン
RU2476594C2 (ru) * 2007-05-04 2013-02-27 Бакстер Интернэшнл Инк. Двухстадийный температурный профиль для культивирования вирусов
US9474798B2 (en) 2007-06-18 2016-10-25 Wisconsin Alumni Research Foundation Influenza M2 protein mutant viruses as live influenza attenuated vaccines
JP2011512877A (ja) * 2008-03-12 2011-04-28 ワイス・エルエルシー 組換えタンパク質の大スケール産生に適した細胞を同定する方法
CA2733356C (en) * 2008-08-01 2016-06-07 Gamma Vaccines Pty Limited Influenza vaccines
CA2738024A1 (en) 2008-09-24 2010-04-01 Medimmune, Llc Methods for purification of viruses
CN103952376A (zh) * 2008-09-24 2014-07-30 米迪缪尼有限公司 培养细胞、增殖和纯化病毒的方法
ES2524975T3 (es) 2009-07-31 2014-12-16 Ge Healthcare Bio-Sciences Corp. Cepa del virus de la fiebre amarilla de alto rendimiento con mayor propagación en células
JP2013507990A (ja) 2009-10-26 2013-03-07 ダブリュエーアールエフ−ウィスコンシン アラムナイ リサーチ ファウンデーション ベロ細胞において増強された複製を有する高力価の組換えインフルエンザウイルス
WO2011077035A1 (fr) * 2009-12-23 2011-06-30 Sanofi Pasteur Procede de culture de cellules adherentes
US10130697B2 (en) 2010-03-23 2018-11-20 Wisconsin Alumni Research Foundation (Warf) Vaccines comprising mutant attenuated influenza viruses
WO2011130119A2 (en) 2010-04-14 2011-10-20 Millipore Corporation Methods of producing high titer, high purity virus stocks and methods of use thereof
EP2625264B1 (en) 2010-10-08 2022-12-07 Terumo BCT, Inc. Methods and systems of growing and harvesting cells in a hollow fiber bioreactor system with control conditions
CN101979517B (zh) * 2010-10-15 2011-12-28 普莱柯生物工程股份有限公司 一种利用生物反应器大规模生产流感病毒的方法
EP2667891B1 (en) 2011-01-27 2021-10-06 Gamma Vaccines Pty Limited Combination vaccines
JP2014527799A (ja) 2011-08-26 2014-10-23 ダブリュエーアールエフ−ウィスコンシン アラムナイ リサーチ ファウンデーション 変異型ｐｂ２遺伝子セグメントを有する弱毒化生ワクチンとしてのインフルエンザウイルス
CN102492659A (zh) * 2011-11-14 2012-06-13 成都康华生物制品有限公司 一种疫苗生产用甲肝病毒的生产方法
EP3022296B1 (en) 2013-07-15 2022-12-28 Wisconsin Alumni Research Foundation High titer recombinant influenza viruses with enhanced replication in mdck or vero cells or eggs
CN103387958B (zh) * 2013-08-16 2016-04-06 北京科兴中维生物技术有限公司 人胚肺成纤维细胞sv-7在病毒培养中的应用
EP3068866B1 (en) 2013-11-16 2018-04-25 Terumo BCT, Inc. Expanding cells in a bioreactor
WO2015148704A1 (en) 2014-03-25 2015-10-01 Terumo Bct, Inc. Passive replacement of media
WO2015196150A2 (en) 2014-06-20 2015-12-23 Wisconsin Alumni Research Foundation (Warf) Mutations that confer genetic stability to additional genes in influenza viruses
US20160090569A1 (en) 2014-09-26 2016-03-31 Terumo Bct, Inc. Scheduled Feed
KR101983486B1 (ko) 2015-01-26 2019-05-28 우베 고산 가부시키가이샤 폴리이미드 다공질막을 이용하는 세포의 대량 배양 방법, 장치 및 키트
US10519478B2 (en) 2015-01-26 2019-12-31 Ube Industries, Ltd. Method of producing substance
US10633422B2 (en) 2015-06-01 2020-04-28 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication by inhibiting microRNA lec7C binding to influenza viral cRNA and mRNA
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
US9890363B2 (en) 2015-07-06 2018-02-13 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication for vaccine development
JP2019510481A (ja) 2016-02-19 2019-04-18 ウィスコンシン アルムニ リサーチ ファンデイション ワクチン開発のための改善されたｂ型インフルエンザウイルス複製
WO2017205667A1 (en) 2016-05-25 2017-11-30 Terumo Bct, Inc. Cell expansion
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
US11932841B2 (en) 2016-07-25 2024-03-19 Ube Corporation Cell cultivation module
JP6897680B2 (ja) 2016-07-25 2021-07-07 宇部興産株式会社 サイフォン式培養法
CN110612344B (zh) 2017-03-31 2023-09-12 泰尔茂比司特公司 细胞扩增
US12234441B2 (en) 2017-03-31 2025-02-25 Terumo Bct, Inc. Cell expansion
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion
EP3700562A1 (en) 2017-10-25 2020-09-02 Wisconsin Alumni Research Foundation (WARF) Recombinant influenza viruses with stabilized ha for replication in eggs
CN111615399A (zh) * 2018-01-18 2020-09-01 依生生物制药(新加坡)私人有限公司 一种使流感病毒适应Vero细胞的方法
SG11202007503WA (en) * 2018-02-07 2020-09-29 Bharat Biotech Int Ltd A process for enterovirus purification and inactivation and vaccine compositions obtained thereof
JP7783047B2 (ja) 2018-08-07 2025-12-09 ウィスコンシン アルムニ リサーチ ファンデイション 組換えの生物学的に封じ込められたフィロウイルスワクチン
EP3840780A1 (en) 2018-08-20 2021-06-30 Wisconsin Alumni Research Foundation Vectors for eliciting immune responses to non-dominant epitopes in the hemagglutinin (ha) protein
EP3914295A2 (en) 2019-01-23 2021-12-01 Yoshihiro Kawaoka Mutations that confer genetic stability to additional genes in influenza viruses
KR102228267B1 (ko) * 2019-01-25 2021-03-17 바이로큐어 주식회사 Bhk-21 세포를 이용한 바이러스 생산방법
WO2020153619A1 (ko) * 2019-01-25 2020-07-30 바이로큐어 주식회사 Bhk-21 세포를 이용한 바이러스 생산방법
US11851648B2 (en) 2019-02-08 2023-12-26 Wisconsin Alumni Research Foundation (Warf) Humanized cell line
AU2020221305A1 (en) * 2019-02-15 2021-08-26 Ology Bioservices, Inc. Method for virus production
WO2020223699A1 (en) 2019-05-01 2020-11-05 Wisconsin Alumni Research Foundation (Warf) Improved influenza virus replication for vaccine development
TW202122569A (zh) 2019-08-09 2021-06-16 日商宇部興產股份有限公司 應用小片多孔膜的細胞培養法
TW202122572A (zh) 2019-08-09 2021-06-16 日商宇部興產股份有限公司 胞外體的產生方法
WO2021041624A2 (en) 2019-08-27 2021-03-04 Yoshihiro Kawaoka Recombinant influenza viruses with stabilized ha for replication in eggs
JP2023511444A (ja) 2020-01-24 2023-03-17 ウィスコンシン アルムニ リサーチ ファンデイション 安定化されたｎａを有する組換えインフルエンザウイルス
US12290562B2 (en) 2020-03-25 2025-05-06 Wisconsin Alumni Research Foundation (Warf) Recombinant multivalent influenza viruses
CN111850169B (zh) * 2020-07-16 2022-09-27 华农（肇庆）生物产业技术研究院有限公司 一种计算AIV在MDCK-sus细胞中细胞单位均产毒量的方法
WO2022204315A1 (en) 2021-03-23 2022-09-29 Terumo Bct, Inc. Cell capture and expansion
US12209689B2 (en) 2022-02-28 2025-01-28 Terumo Kabushiki Kaisha Multiple-tube pinch valve assembly
USD1099116S1 (en) 2022-09-01 2025-10-21 Terumo Bct, Inc. Display screen or portion thereof with a graphical user interface for displaying cell culture process steps and measurements of an associated bioreactor device

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4525349A (en) 1981-12-29 1985-06-25 Societe Anonyme Dite: Institut Merueux Process for the large-scale production of a vaccine against poliomyelitis and the resulting vaccine
AT393356B (de) 1989-12-22 1991-10-10 Immuno Ag Verfahren zur herstellung von fsme-virus-antigen
US5719051A (en) * 1989-12-22 1998-02-17 Immuno Aktiengesellschaft Perfusion system and a method for the large scale production of virus or virus antigen
FR2723740B1 (fr) 1994-08-16 1996-11-08 Pasteur Merieux Serums Vacc Procede de preparation d'antigenes du virus grippal, antigenes obtenus et leurs applications
US5824536A (en) * 1994-08-23 1998-10-20 St. Jude Children's Research Hospital Influenza virus replicated in mammalian cell culture and vaccine production
DK0791055T3 (da) 1994-11-10 2012-04-16 Baxter Healthcare Sa Fremgangsmåde til fremstilling af biologiske produkter i proteinfri kultur
DE19612966B4 (de) * 1996-04-01 2009-12-10 Novartis Vaccines And Diagnostics Gmbh & Co. Kg MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren
GB2319413B (en) * 1996-11-12 2001-06-06 Lsi Logic Corp Driver circuits
US6168944B1 (en) * 1997-01-31 2001-01-02 Schering Corporation Methods for cultivating cells and propagating viruses
DE69835813T2 (de) * 1997-01-31 2007-09-13 Schering Corp. Verfahren zur kultivierung von zellen und zur vermehrung von viren
AT407255B (de) 1997-06-20 2001-02-26 Immuno Ag Rekombinanter zellklon mit erhöhter stabilität in serum- und proteinfreiem medium und verfahren zur gewinnung des stabilen zellklons
US5994134A (en) * 1998-05-04 1999-11-30 Canji, Inc. Viral production process
US6855535B2 (en) * 2001-12-10 2005-02-15 Baxter Healthcare S.A. Method of large scale production of Hepatitis A virus
US6951752B2 (en) * 2001-12-10 2005-10-04 Bexter Healthcare S.A. Method for large scale production of virus antigen

Also Published As

Publication number Publication date
HK1115609A1 (en) 2008-12-05
DE122010000025I1 (de) 2010-08-12
AU2002358662B2 (en) 2008-05-15
FR10C0026I1 (fr) 2011-01-14
RU2314344C2 (ru) 2008-01-10
HUP0402415A3 (en) 2005-07-28
DK1453956T3 (da) 2010-01-11
JP5021000B2 (ja) 2012-09-05
ES2335395T3 (es) 2010-03-26
CN101100657A (zh) 2008-01-09
EP2330189B1 (en) 2014-05-21
HK1158691A1 (en) 2012-07-20
CN1617924A (zh) 2005-05-18
CN100335619C (zh) 2007-09-05
ES2488818T3 (es) 2014-08-29
WO2003054174A1 (en) 2003-07-03
US20050181495A1 (en) 2005-08-18
EP1894998A8 (en) 2008-04-23
JP2005512564A (ja) 2005-05-12
ATE447010T2 (de) 2009-11-15
EP1453956A1 (en) 2004-09-08
AU2002358662A1 (en) 2003-07-09
ES2335395T5 (es) 2017-08-31
EP1894998A1 (en) 2008-03-05
JP4370511B2 (ja) 2009-11-25
EP1453956B8 (en) 2010-02-10
CA2469644A1 (en) 2003-07-03
JP2009261410A (ja) 2009-11-12
HU225791B1 (en) 2007-09-28
DE60234211D1 (de) 2009-12-10
EP2330189A1 (en) 2011-06-08
MXPA04005644A (es) 2005-04-19
NO20042910L (no) 2004-07-09
EP1453956B2 (en) 2017-01-18
RU2004121178A (ru) 2005-10-10
US20030108860A1 (en) 2003-06-12
PL208232B1 (pl) 2011-04-29
US6951752B2 (en) 2005-10-04
HUP0402415A2 (hu) 2005-02-28
DK2330189T3 (da) 2014-06-16
PL373487A1 (en) 2005-09-05
EP1453956B1 (en) 2009-10-28
US7524676B2 (en) 2009-04-28
CN101100657B (zh) 2012-05-30

Similar Documents

Publication Publication Date Title
CA2469644C (en) Method for large scale production of virus antigen
CA2455189C (en) Methods for producing an active constituent of a pharmaceutical or a diagnostic agent in an mdck cell suspension culture
AU2002338666B2 (en) Multiplication of viruses in a cell culture
IL190578A (en) A viro cell line and a method to create a virus to prepare vaccines from it
HK1158691B (en) Method for large scale production of virus
HK1116825A (en) Method for large scale production of virus
HK1115609B (en) Method for large scale production of virus antigen
HK1062030B (en) Methods for the industrial production of vaccines

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20221212